Glioblastoma (GBM) is an aggressive type of brain cancer that escapes most drug treatments. Only 15-20% of patients survive more than 5 years with the usual treatment currently available (surgery, radiation, and chemotherapy using temozolomide).

In this study, a treatment regimen with 9 different drugs (CUSP9v3) in addition to low-dose, continuous temozolomide was devised to tackle this issue.

The conclusion is that CUSP9v3 can be safely administered to patients with recurrent GBM.